TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
C4 Therapeutics ( (CCCC) ) has shared an update.
On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
C4 Therapeutics’ stock score is primarily impacted by its financial struggles, with ongoing losses and negative cash flows. Technical indicators suggest weak market momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted protein degradation therapies. The company aims to create innovative treatments for diseases by harnessing the body’s natural protein degradation pathways.
Average Trading Volume: 1,804,697
Technical Sentiment Signal: Sell
Current Market Cap: $158M
For an in-depth examination of CCCC stock, go to TipRanks’ Overview page.